Get the Stockscreener App
0.61
5.15%
0.0299
After Hours:
.62
0.01
+1.64%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Vaxart Inc stock is traded at $0.61, with a volume of 2.64M.
It is up +5.15% in the last 24 hours and down -25.58% over the past month.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
See More
Previous Close:
$0.5801
Open:
$0.595
24h Volume:
2.64M
Relative Volume:
1.50
Market Cap:
$141.06M
Revenue:
$9.10M
Net Income/Loss:
$-82.47M
P/E Ratio:
-0.8026
EPS:
-0.76
Net Cash Flow:
$-72.32M
1W Performance:
-12.08%
1M Performance:
-25.58%
6M Performance:
-36.38%
1Y Performance:
-23.65%
1-Day Range:
$0.5801
$0.6399
1-Week Range:
$0.58
$0.75
52-Week Range:
$0.52
$1.54
Vaxart Inc Stock (VXRT) Company Profile
Name
Vaxart Inc
Sector
Industry
Phone
(650) 550-3500
Address
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VXRT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| VXRT | 0.61 | 141.06M | 9.10M | -82.47M | -72.32M | -0.76 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-21 | Resumed | Jefferies | Buy |
| Nov-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-29-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jun-24-21 | Initiated | Jefferies | Buy |
| Jun-11-21 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
View All
Vaxart Inc Stock (VXRT) Latest News
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding - Simply Wall St
Vaxart Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Vaxart, Inc. Reports Third Quarter 2024 Financial Results – - Defense World
Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Call Transcript - Insider Monkey
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Earnings call: Vaxart reports progress in vaccine programs and financial growth - Investing.com
Vaxart Inc (NASDAQ: VXRT): Blank Check On Growth? - Stocks Register
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and Financial Growth - GuruFocus.com
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ... - Yahoo Finance
Vaxart Inc reports results for the quarter ended September 30Earnings Summary - XM
Vaxart’s Q3 2024: Progress in Oral Vaccine Development - TipRanks
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Vaxart's Q3 Revenue Jumps 133% to $4.9M, Narrows Losses Amid COVID Trial Progress | VXRT Stock News - StockTitan
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results - Yahoo Finance
Vaxart (VXRT) Scheduled to Post Earnings on Wednesday - MarketBeat
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13 - The Manila Times
Vaxart (VXRT) Sets Q3 2024 Earnings Call for November 13: Key Updates Coming | VXRT Stock News - StockTitan
While shareholders of Vaxart (NASDAQ:VXRT) are in the black over 5 years, those who bought a week ago aren't so fortunate - Simply Wall St
Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain - Yahoo Finance
VXRTVaxart, Inc Latest Stock News & Market Updates - StockTitan
Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving AverageShould You Sell? - MarketBeat
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024 - StockTitan
Millennium Management LLC Has $2.66 Million Stock Holdings in Vaxart, Inc. (NASDAQ:VXRT) - MarketBeat
Check out these key findings about Vaxart Inc (VXRT) - SETE News
Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need - StockTitan
VXRT stock rated an Outperform by Oppenheimer - Knox Daily
Did Vaxart Inc (VXRT) perform well in the last session? - US Post News
Best Penny Stocks Under $1 To Buy Now - AOL
Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances - Yahoo Finance
Vaxart ends agreement with sales agents, halts stock sales By Investing.com - Investing.com Australia
Vaxart, Inc. Terminates Controlled Equity Offering Sales Agreement with Sales Agents - MarketBeat
Vaxart ends agreement with sales agents, halts stock sales - Investing.com India
Vaxart Ends Sales Agreement, Halts Stock Offering - TipRanks
The growth track for Vaxart Inc (VXRT) has changed recently - SETE News
Vaxart (NASDAQ:VXRT) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
Vaxart Inc (VXRT) Stock: A Year of Declines and Increases - The InvestChronicle
Vaxart Inc [VXRT] Shares Rise 4.78 % on Wednesday - Knox Daily
Vaxart Initiates Phase 2b Study of Oral COVID-19 Vaccine - Contagionlive.com
It makes sense and dollars to buy Vaxart Inc (VXRT) stock - SETE News
Dr. Wouter Latour Joins PharmaJet as Chief Executive Officer - BioSpace
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine - EIN News
Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - StockTitan
Vaxart (NASDAQ:VXRT) Shares Pass Above 200-Day Moving Average of $0.84 - MarketBeat
The Sherwin-Williams Company (NYSE:SHW) Shares Sold by Kingfisher Capital LLC - Defense World
Does Vaxart Inc (VXRT) offer a good opportunity for investors? - SETE News
Stocks to Watch Tuesday: Visa, Deere, Baidu, Alibaba, Smartsheet - The Wall Street Journal
Vaxart Inc (VXRT)’s stock rises to 0.84 per share - US Post News
YUM CHINA Largest Self-built Supply Chain Center Put into Operation in Jiading, Shanghai - AASTOCKS.com
Upward Trajectory: Vaxart Inc (VXRT) Posts a Slidee, Closing at 0.83 - The Dwinnex
Cathay Cargo and Menzies agree south-west Pacific contract renewal - Aviation Business News
Vaxart Inc Stock (VXRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):